Novo Nordisk upgrades guidance

The Danish pharmaceutical giant has upgraded its full-year financial guidance due to the growth in market shares for diabetes drug Ozempic being higher than expected and market growth for the other GLP analogs. Obesity drug sales, mostly in the US, are also highlighted as significant.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by christopher due karlsson, translated by catherine brett

Novo Nordisk has raised its sales and operating outlook for 2021.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading